Enzalutamide + Enzalutamide with Sorafenib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Trial Timeline
Dec 1, 2015 → Mar 1, 2021
NCT ID
NCT02642913About Enzalutamide + Enzalutamide with Sorafenib
Enzalutamide + Enzalutamide with Sorafenib is a phase 1 stage product being developed by Astellas Pharma for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02642913. Target conditions include Hepatocellular Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02642913 | Phase 1 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma